# Michael Benatar

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/michael-benatar/

## Facts

| Field | Value |
| --- | --- |
| Citations | 25,887 |
| Field | Amyotrophic Lateral Sclerosis Research |
| h-index | 71 |
| i10-index | 187 |
| Last Known Institution | University of Miami |
| OpenAlex ID | https://openalex.org/A5031062952 |
| ORCID iD | https://orcid.org/0000-0003-4241-5135 |
| Works | 564 |

## Researcher papers

Showing 12 of 16.

- [A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD](https://scholariq.org/papers/a-hexanucleotide-repeat-expansion-in-c9orf72-is-the-cause-of-chromosome-9p21/)
- [Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS](https://scholariq.org/papers/mutations-in-prion-like-domains-in-hnrnpa2b1-and-hnrnpa1-cause-multisystem/)
- [Exome Sequencing Reveals VCP Mutations as a Cause of Familial ALS](https://scholariq.org/papers/exome-sequencing-reveals-vcp-mutations-as-a-cause-of-familial-als/)
- [International consensus guidance for management of myasthenia gravis](https://scholariq.org/papers/international-consensus-guidance-for-management-of-myasthenia-gravis/)
- [Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria](https://scholariq.org/papers/amyotrophic-lateral-sclerosis-frontotemporal-spectrum-disorder-als-ftsd-revised/)
- [Randomized Trial of Thymectomy in Myasthenia Gravis](https://scholariq.org/papers/randomized-trial-of-thymectomy-in-myasthenia-gravis/)
- [Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS](https://scholariq.org/papers/trial-of-antisense-oligonucleotide-tofersen-for-i-sod1-i-als/)
- [Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study](https://scholariq.org/papers/safety-and-efficacy-of-eculizumab-in-anti-acetylcholine-receptor-antibody/)
- [International Consensus Guidance for Management of Myasthenia Gravis](https://scholariq.org/papers/international-consensus-guidance-for-management-of-myasthenia-gravis-2/)
- [Controversies and priorities in amyotrophic lateral sclerosis](https://scholariq.org/papers/controversies-and-priorities-in-amyotrophic-lateral-sclerosis/)
- [Poly(GP) proteins are a useful pharmacodynamic marker for <i>C9ORF72</i> -associated amyotrophic lateral sclerosis](https://scholariq.org/papers/poly-gp-proteins-are-a-useful-pharmacodynamic-marker-for-i-c9orf72-i-associated/)
- [Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis](https://scholariq.org/papers/long-term-safety-and-efficacy-of-eculizumab-in-generalized-myasthenia-gravis/)

## Researcher topics

- [Amyotrophic Lateral Sclerosis Research](https://scholariq.org/topics/amyotrophic-lateral-sclerosis-research/)
- [Neurogenetic and Muscular Disorders Research](https://scholariq.org/topics/neurogenetic-and-muscular-disorders-research/)
- [Myasthenia Gravis and Thymoma](https://scholariq.org/topics/myasthenia-gravis-and-thymoma/)
- [Genetic Neurodegenerative Diseases](https://scholariq.org/topics/genetic-neurodegenerative-diseases/)
- [Peripheral Neuropathies and Disorders](https://scholariq.org/topics/peripheral-neuropathies-and-disorders/)

## Researcher university

- [University of Miami](https://scholariq.org/institutions/university-of-miami/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.